Testing TQB3455 tablets for blood cancers with IDH2 mutation
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new tablet, TQB3455, for people with certain blood cancers (MDS or AML) that have an IDH2 mutation. The goal is to see if the drug can help when other treatments haven't worked or aren't possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a type of blood cancer called MDS or AML, and it's either hard to treat, has come back, or is high-risk.
- Your cancer cells have a specific change called an IDH2 mutation.
- Your platelet count (a type of blood cell) is at least 20,000, or if lower, it's because of the cancer.
- You have not taken a drug that targets IDH2 before.
- Your liver, kidneys, and heart are working well enough, and you are healthy enough to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called TQB3454 in people with advanced solid tumors, including brain tumors (gliomas) and bile duct cancer. The drug targets a specific gene change (IDH1) that may help control tumor growth. Participation may offer a new treatment option when standard treatments have stopped working.
This study tests an experimental pill (TQB3911) for people with chronic myeloid leukemia (CML) who have not responded well to or could not tolerate standard treatments. The goal is to find out if the drug is safe and what side effects it may cause.
This trial tests a combination of three drugs (venetoclax, ivosidenib, and azacitidine) for people newly diagnosed with a specific type of AML that has an IDH1 mutation. The goal is to see if this mix works better than standard treatments.
This trial tests an experimental oral capsule called TQB3019 for people with advanced blood cancers that have come back or not improved with other treatments. The goal is to see if the drug is safe and to find the right dose.
This trial tests a new oral drug, TQB3909, combined with a standard chemotherapy drug (azacitidine) for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if this combination is safe and effective.
This trial tests a new drug called TQB2101 for people with advanced blood cancers that haven't improved with standard treatments. The goal is to see if the drug is safe and effective.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.